CADILA HEALTHCARE LTD. - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate12-04-2019
12-04-2019
Cadila Healthcare Ltd - 532321 - Compliance Certificate Under Regulation 7(3)
Compliance Certificate under regulation 7(3)12-04-2019
Cadila Healthcare Ltd - 532321 - The Company Proposes To Submit Audited Financial Results For The Entire Financial Year Ended On March 31, 2019 Instead Of Providing Unaudited Financial Results For The Quarter Ended On March 31, 2019. In View Of The Above, The Company Shall Provide To The Exchange Audited Financial Results For The Year Ended March 31, 2019 Within 60 Days From The End Of The Financial Year.
The Company proposes to submit audited financial results for the entire financial year ended on March 31, 2019 instead of providing unaudited financial results for the quarter ended on March 31, 2019. In view of the above, the Company shall provide to the exchange audited financial results for the year ended March 31, 2019 within 60 days from the end of the Financial Year.12-04-2019
CADILA HEALTHCARE LTD. - 532321 - Certificate Under Regulation 40(10)
Certificate under Regulation 40(10)12-04-2019
CADILA HEALTHCARE LTD. - 532321 - Statement Of Investor Complaints For The Quarter Ended March 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 19100 Name of the Signatory :- Dhaval N. SoniDesignation :- Company Secretary and Compliance Officer12-04-2019
CADILA HEALTHCARE LTD. - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate11-04-2019
Zydus Cadila gets tentative USFDA nod to market generic anti-epileptic tablets
Drug firm Zydus Cadila on Monday said it has has received a tentative nod from the US health regulator for marketing generic Lacosamide tablets, used08-04-2019
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives tentative approval from the USFDA for Tofacitinib Tablets06-04-2019
Cadila Healthcare Ltd - 532321 - Closure of Trading Window
Intimation of Closure of Trading Window03-04-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
We hereby inform that the USFDA inspected the Company's formulations manufacturing facility located at Pharmez, Ahmedabad from 25th March 2019 to 2nd April 2019. The inspection which included product specific pre-approval and post-approval inspections and a GMP inspection, concluded with one observation. The Company is confident of addressing the observation at the earliest.03-04-2019